---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-022371"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-25T00:11:25.512990+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apogee Therapeutics enters manufacturing agreement with Samsung Biologics for APG777 drug substance

## Summary
- Master Services Agreement with Samsung Biologics for manufacture and supply of APG777 drug substance for clinical development and commercial sale if approved.
- Initial Project Specific Agreement for clinical batches, process characterization/validation, and process performance qualification lots at Samsung's Incheon facility.
- Minimum purchase quantities under Initial PSA; commercial supply PSA from 2029-2034 with minimum commitments; exit fee high single digit millions if not entered.
- MSA terminates February 2035; Initial PSA terminates December 2034; termination rights for material breach, insolvency, force majeure.
- Upon termination, Samsung to assist with technology transfer; without-cause termination results in payment for remaining product commitment.

## SEC filing metadata
- accession: 0001104659-25-022371
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465925022371/0001104659-25-022371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465925022371/tm258743d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-022371
- JSON: https://secwatch.observer/filing/0001104659-25-022371.json
- Plain text: https://secwatch.observer/filing/0001104659-25-022371.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.